Ocular Therapeutix (OCUL) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Septerna (SEPN) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 71.3% versus a loss of 37.2%. Septerna is the larger company by market cap ($1.68 billion vs $1.59 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCUL | SEPN |
|---|---|---|
| Share price | $7.23 | $36.00 |
| Market cap | $1.59B | $1.68B |
| 1-day change | -1.50% | +0.93% |
| YTD return | -40.44% | +29.12% |
| 1-year return | -37.24% | +71.35% |
| 5-year return | -35.39% | — |
| EPS (TTM) | $-1.40 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.44 | $51.10 |
| 52-week low | $6.23 | $17.55 |
| Distance from 52-week high | -56.02% | -29.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +274.69% | +50.61% |
| Average volume | 2.78M | 392.67K |
| Shares outstanding | 219.62M | 46.68M |
| Employees | 325 | 123 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed OCUL by 108.6 percentage points over the past year.
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
OCUL vs SEPN FAQ
Which is bigger, Ocular Therapeutix or Septerna?
Septerna (SEPN) is larger, with a market capitalization of $1.68B compared with $1.59B for Ocular Therapeutix (OCUL).
Which stock has performed better over the past year, OCUL or SEPN?
SEPN returned +71.35% over the past 12 months, compared with -37.24% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Ocular Therapeutix and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.